Moleculin Biotech (MBRX) News Today $0.50 -0.01 (-1.06%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$0.50 0.00 (-0.52%) As of 07:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Moleculin Biotech announces issuance of Canadian patent covering AnnamycinSeptember 26, 2025 | finance.yahoo.comMoleculin Biotech Secures Canadian Patent for AnnamycinSeptember 25, 2025 | msn.comMoleculin Announces Notice of Allowance for Canadian Patent Covering AnnamycinSeptember 25, 2025 | globenewswire.comMoleculin Biotech files to sell 64.86M shares of common stock for holdersSeptember 19, 2025 | msn.comMoleculin Biotech accelerates recruitment in Phase 3 MIRACLE trialSeptember 10, 2025 | finance.yahoo.comMoleculin Biotech, Inc. Expands Global Recruitment for MIRACLE Trial in Europe and the US, Aiming for 45 Patients by Q4 2025September 9, 2025 | quiverquant.comQMoleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical TrialSeptember 9, 2025 | globenewswire.comMoleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid LeukemiaSeptember 8, 2025 | globenewswire.comMoleculin Biotech Completes Promising Annamycin TrialAugust 29, 2025 | msn.comMoleculin Biotech announces OS data from Phase 1B/2 clinical trial in AMLAugust 28, 2025 | msn.comMoleculin Announces Exercise of Warrants for $6.0 Million Gross ProceedsAugust 28, 2025 | globenewswire.comMoleculin Issues New Positive AML Overall Survival Data:August 27, 2025 | globenewswire.comMoleculin Biotech Holds 2025 Annual Stockholders MeetingAugust 19, 2025 | msn.comMoleculin Biotech Releases New Corporate PresentationAugust 19, 2025 | msn.comMoleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comMoleculin Biotech Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comMoleculin Biotech, Inc.: Moleculin Reports Second Quarter 2025 Financial Results and HighlightsAugust 14, 2025 | finanznachrichten.deMoleculin Biotech reports Q2 EPS (49c) vs. ($1.70) last yearAugust 14, 2025 | msn.comMoleculin Biotech sees cash runway into Q4August 14, 2025 | msn.comMoleculin Reports Second Quarter 2025 Financial Results and HighlightsAugust 13, 2025 | globenewswire.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer ...August 6, 2025 | gurufocus.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer TreatmentAugust 6, 2025 | gurufocus.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer TreatmentAugust 6, 2025 | globenewswire.comMoleculin Biotech Releases Corporate Presentation UpdateAugust 1, 2025 | tipranks.comMoleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 31, 2025 | finanznachrichten.deMoleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 30, 2025 | globenewswire.comMoleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comMoleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comMoleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic PartnershipsJuly 17, 2025 | globenewswire.comMoleculin Biotech enters $6.5 million at-the-market equity offering ...July 13, 2025 | investing.comMoleculin Biotech Enters New Stock Offering AgreementJuly 11, 2025 | tipranks.comMoleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 ... - NasdaqJuly 11, 2025 | nasdaq.comMoleculin Biotech, Inc.: Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future PlansJuly 9, 2025 | finanznachrichten.deMoleculin Biotech receives approval for pivotal Phase 2B/3 study of AnnamycinJuly 9, 2025 | msn.comMoleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future PlansJuly 9, 2025 | globenewswire.comSeveral Insiders Invested In Moleculin Biotech Flagging Positive NewsJuly 4, 2025 | finance.yahoo.comMoleculin Biotech Faces Nasdaq Delisting WarningJune 27, 2025 | tipranks.comMBRX Moleculin Biotech, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comMoleculin Biotech, Inc. (NASDAQ:MBRX) CFO Acquires $99,999.90 in StockJune 24, 2025 | insidertrades.comMoleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AMLJune 20, 2025 | nasdaq.comMoleculin Biotech prices $5.9M public offering; shares down about 47%June 20, 2025 | msn.comMoleculin Biotech, Inc. Announces Pricing of $5.9 Million Public Offering of Common Stock and Series E WarrantsJune 20, 2025 | quiverquant.comQMoleculin Announces $5.9 Million Public OfferingJune 20, 2025 | globenewswire.comMoleculin Biotech, Inc.: Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18, 2025 | finanznachrichten.deMoleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical StudyJune 18, 2025 | quiverquant.comQMoleculin Participates in Virtual Investor “What This Means” SegmentJune 18, 2025 | globenewswire.comMoleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18, 2025 | globenewswire.comMoleculin Biotech announces ‘What This Means’ virtual investor segmentJune 12, 2025 | finance.yahoo.comMoleculin Participates in Virtual Investor “What This Means” SegmentJune 11, 2025 | globenewswire.comMoleculin Biotech Hosts Key Opinion Leaders EventJune 5, 2025 | tipranks.com Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.000.50▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼02▲MBRX Articles Average Week Get the Latest News and Ratings for MBRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Moleculin Biotech and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CNTB News Today QNCX News Today ORMP News Today IPA News Today CLNN News Today SPRB News Today ANEB News Today ENTX News Today ADAG News Today CRDL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBRX Stock Alerts